MCID: INF037
MIFTS: 54

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 36 29 6 3 15 17
Inflammatory Bowel Diseases 54 43 15 71
Bowel Disease, Inflammatory 39

Classifications:



External Ids:

Disease Ontology 12 DOID:0050589
KEGG 36 H01227
MeSH 43 D015212
NCIt 49 C3138
SNOMED-CT 67 24526004
UMLS 71 C0021390

Summaries for Inflammatory Bowel Disease

KEGG : 36 Inflammatory bowel disease (IBD) is a heterogeneous group of chronic disorders, which includes Crohn's disease and ulcerative colitis. Patients suffer chronically from abdominal pain, diarrhea, bleeding, and malabsorption. In most patients, these disorders are manifested in adolescence or adulthood, however, they may present in infancy and may be inherited as an autosomal recessive trait. It has been reported that mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Additional genes associated with the disease have been identified.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 8 and inflammatory bowel disease 7. An important gene associated with Inflammatory Bowel Disease is NRON (Non-Coding Repressor Of NFAT), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Antigen processing and presentation. The drugs Copper and Clofazimine have been mentioned in the context of this disorder. Affiliated tissues include all parts of digestive tract, colon and t cells.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

Wikipedia : 74 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Related Diseases for Inflammatory Bowel Disease

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25 Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1182)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 8 35.3 NOD2 IBD8
2 inflammatory bowel disease 7 35.3 NOD2 IBD7
3 inflammatory bowel disease 9 35.3 NOD2 IBD9
4 inflammatory bowel disease 6 35.2 NOD2 IBD6
5 inflammatory bowel disease 3 35.1 NOD2 IBD3
6 inflammatory bowel disease 2 35.0 NOD2 IBD2
7 inflammatory bowel disease 5 34.8 NOD2 IBD5
8 inflammatory bowel disease 25, autosomal recessive 12.9
9 inflammatory bowel disease 1 12.9
10 inflammatory bowel disease 10 12.9
11 inflammatory bowel disease 17 12.9
12 inflammatory bowel disease 19 12.9
13 inflammatory bowel disease 28, autosomal recessive 12.9
14 inflammatory bowel disease 14 12.8
15 inflammatory bowel disease 13 12.8
16 inflammatory bowel disease, immunodeficiency, and encephalopathy 12.8
17 inflammatory bowel disease 29 12.8
18 inflammatory bowel disease 18 12.8
19 inflammatory bowel disease 4 12.8
20 inflammatory bowel disease 20 12.8
21 inflammatory bowel disease 15 12.8
22 inflammatory bowel disease 24 12.8
23 inflammatory bowel disease 28 12.8
24 inflammatory bowel disease 12 12.8
25 inflammatory bowel disease 16 12.8
26 inflammatory bowel disease 21 12.8
27 inflammatory bowel disease 26 12.8
28 inflammatory bowel disease 22 12.8
29 inflammatory bowel disease 23 12.8
30 inflammatory bowel disease 27 12.8
31 inflammatory bowel disease 11 12.8
32 inflammatory bowel disease 25 12.8
33 ulcerative colitis 12.4
34 inflammatory bowel disease-recurrent sinopulmonary infections syndrome 12.4
35 immune dysregulation with inflammatory bowel disease 12.4
36 immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 12.4
37 rare inflammatory bowel disease 12.4
38 gastrointestinal defects and immunodeficiency syndrome 12.2
39 crohn's disease 12.1
40 cholangitis, primary sclerosing 11.9
41 crohn's colitis 11.8
42 irritable bowel syndrome 11.8
43 spondyloarthropathy 1 11.7
44 ileitis 11.7
45 immunodeficiency, common variable, 8, with autoimmunity 11.7
46 colitis 11.7
47 ileocolitis 11.7
48 immunodeficiency, common variable, 11 11.7
49 collagenous colitis 11.7
50 glycogen storage disease ib 11.6

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease

Symptoms & Phenotypes for Inflammatory Bowel Disease

Drugs & Therapeutics for Inflammatory Bowel Disease

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 491)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Copper Approved, Investigational Phase 4 7440-50-8 27099
2
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
3
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
4
Prucalopride Approved Phase 4 179474-81-8
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Fidaxomicin Approved Phase 4 873857-62-6
7
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
8
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
11
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Bisacodyl Approved Phase 4 603-50-9
15
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
16
Acetaminophen Approved Phase 4 103-90-2 1983
17 Orange Approved Phase 4
18
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
19 Strawberry Approved Phase 4
20 Artichoke Approved Phase 4
21
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
22
Infliximab Approved Phase 4 170277-31-3
23
leucovorin Approved Phase 4 58-05-9 6006 143
24
carbamide peroxide Approved Phase 4 124-43-6
25
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
26
Clarithromycin Approved Phase 4 81103-11-9 84029
27
Zinc oxide Approved Phase 4 1314-13-2
28
Ondansetron Approved Phase 4 99614-02-5 4595
29
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
30
Vancomycin Approved Phase 4 1404-90-6 14969 441141
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
33
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
34
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
35
Racepinephrine Approved Phase 4 329-65-7 838
36
Ustekinumab Approved, Investigational Phase 4 815610-63-0
37
Tofacitinib Approved, Investigational Phase 4 477600-75-2
38
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
39
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
40
Dalteparin Approved Phase 4 9005-49-6
41
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
43
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
44
Rebamipide Investigational Phase 4 90098-04-7
45
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
46 Retinol palmitate Phase 4
47 retinol Phase 4
48 Copper Supplement Phase 4
49 Antacids Phase 4
50 Anti-Ulcer Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1526)
# Name Status NCT ID Phase Drugs
1 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
3 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
4 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
5 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
6 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
7 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
8 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
9 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
10 Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis Unknown status NCT02675153 Phase 4 Sirolimus;5-ASA, Prednisone, Azathioprine or Remicade
11 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
12 EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN Unknown status NCT01711437 Phase 4
13 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
14 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
15 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
16 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
18 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
19 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
20 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
21 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
22 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
23 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
24 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
25 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
26 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
27 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
28 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
29 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
30 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
31 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
32 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
33 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
34 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
35 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
36 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
37 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
38 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
39 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
40 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
41 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
42 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
43 Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis. Completed NCT01737983 Phase 4
44 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
45 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
46 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
47 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
48 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
49 2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial Completed NCT01865916 Phase 4 Polyethylene Glycol (PEG) and 15 mg Bisacodyl;Polyethylene Glycol (PEG) + ascorbic acid
50 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


clidinium
Clidinium bromide
Cromolyn
Cromolyn Sodium

Cochrane evidence based reviews: inflammatory bowel diseases

Genetic Tests for Inflammatory Bowel Disease

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 29

Anatomical Context for Inflammatory Bowel Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

19
All Parts Of Digestive Tract

MalaCards organs/tissues related to Inflammatory Bowel Disease:

40
Colon, T Cells, Bone, Liver, Testes, Neutrophil, Skin

Publications for Inflammatory Bowel Disease

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 36633)
# Title Authors PMID Year
1
Association analysis of myosin IXB and type 1 diabetes. 61 54
20303373 2010
2
Anti-TNF therapy in inflammatory bowel diseases: a huge review. 61 54
20485259 2010
3
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. 54 61
20361960 2010
4
IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease. 54 61
20229252 2010
5
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. 61 54
20485703 2010
6
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. 61 54
20493732 2010
7
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 54 61
20228197 2010
8
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 61 54
20454450 2010
9
Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease. 61 54
20184972 2010
10
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. 54 61
19710105 2010
11
The use of GLP-2 and related growth factors in intestinal diseases. 61 54
20336592 2010
12
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. 54 61
20138213 2010
13
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. 54 61
20061984 2010
14
Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. 54 61
19878610 2010
15
GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. 61 54
20331905 2010
16
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. 54 61
19714744 2010
17
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. 54 61
19960028 2010
18
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. 54 61
20175817 2010
19
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 61 54
20446955 2010
20
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. 54 61
20210765 2010
21
[Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications]. 61 54
20158097 2010
22
[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 61 54
20160771 2010
23
Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. 54 61
19698701 2010
24
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. 54 61
19808045 2010
25
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia. 61 54
20101775 2010
26
Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. 61 54
20066736 2010
27
Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease. 54 61
19885626 2009
28
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. 54 61
19740775 2009
29
Actobiotics as a novel method for cytokine delivery. 54 61
20074282 2009
30
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. 61 54
19363798 2009
31
Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. 54 61
19575361 2009
32
Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 61 54
19639558 2009
33
The role of resistin as a regulator of inflammation: Implications for various human pathologies. 54 61
19740705 2009
34
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. 61 54
19839006 2009
35
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 54 61
19473188 2009
36
Interleukin-10 in inflammatory bowel disease. 61 54
19890110 2009
37
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. 54 61
19874614 2009
38
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. 54 61
19817673 2009
39
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? 54 61
19711064 2009
40
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. 61 54
19462432 2009
41
A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. 54 61
19740306 2009
42
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. 54 61
19648026 2009
43
[TNF-alpha blocking therapy in chronic inflammatory bowel disease]. 61 54
19740722 2009
44
Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. 61 54
19322899 2009
45
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. 61 54
19291780 2009
46
pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. 61 54
19570976 2009
47
[The cytokines in inflammatory bowel disease]. 54 61
19724079 2009
48
Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. 54 61
19604082 2009
49
Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. 61 54
19516190 2009
50
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 61 54
19682195 2009

Variations for Inflammatory Bowel Disease

ClinVar genetic disease variations for Inflammatory Bowel Disease:

6 (show all 14) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL10 NM_000572.3(IL10):c.94C>A (p.His32Asn)SNV Uncertain significance 526787 rs376787667 1:206945687-206945687 1:206772342-206772342
2 IL10 NM_000572.3(IL10):c.58C>T (p.Pro20Ser)SNV Uncertain significance 526788 rs141219090 1:206945723-206945723 1:206772378-206772378
3 IL10 NM_000572.3(IL10):c.514A>G (p.Met172Val)SNV Uncertain significance 662170 1:206942004-206942004 1:206768659-206768659
4 IL10 NM_000572.3(IL10):c.134G>A (p.Arg45Gln)SNV Uncertain significance 840379 1:206945647-206945647 1:206772302-206772302
5 IL10RB NM_000628.5(IL10RB):c.*365C>TSNV Uncertain significance 339702 rs886057005 21:34669027-34669027 21:33296722-33296722
6 IL10RB NM_000628.5(IL10RB):c.*616deldeletion Uncertain significance 339706 rs5843596 21:34669259-34669259 21:33296954-33296954
7 IL10RB NM_000628.5(IL10RB):c.*593_*594TC[1]short repeat Uncertain significance 339705 rs886057007 21:34669255-34669256 21:33296950-33296951
8 IL10RA NM_001558.4(IL10RA):c.*356dupduplication Likely benign 302563 rs146951811 11:117870710-117870711 11:117999995-117999996
9 IL10 NM_000572.3(IL10):c.345C>T (p.Asn115=)SNV Likely benign 745482 1:206944285-206944285 1:206770940-206770940
10 IL10 NM_000572.3(IL10):c.336G>C (p.Leu112=)SNV Likely benign 757750 1:206944294-206944294 1:206770949-206770949
11 IL10 NM_000572.3(IL10):c.228T>C (p.Gly76=)SNV Likely benign 756187 1:206944402-206944402 1:206771057-206771057
12 IL10 NM_000572.3(IL10):c.56G>A (p.Ser19Asn)SNV Likely benign 729261 1:206945725-206945725 1:206772380-206772380
13 IL10 NM_000572.3(IL10):c.165+8T>CSNV Benign 729486 1:206945608-206945608 1:206772263-206772263
14 IL10RB NM_000628.5(IL10RB):c.*615_*616deldeletion Benign 339707 rs5843596 21:34669259-34669260 21:33296954-33296955

Expression for Inflammatory Bowel Disease

Search GEO for disease gene expression data for Inflammatory Bowel Disease.

Pathways for Inflammatory Bowel Disease

Pathways related to Inflammatory Bowel Disease according to KEGG:

36
# Name Kegg Source Accession
1 Inflammatory bowel disease (IBD) hsa05321
2 Antigen processing and presentation hsa04612
3 Cytokine-cytokine receptor interaction hsa04060
4 JAK-STAT signaling pathway hsa04630
5 Autophagy - animal hsa04140

GO Terms for Inflammatory Bowel Disease

Sources for Inflammatory Bowel Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....